NCT00817271View on ClinicalTrials.gov

To Evaluate the Response to Glucagon During Hypoglycemia

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions
Type 2 Diabetes
Interventions
DRUG

AZD1656

Dose titration of oral suspension during 2 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose for another 6 days. On day 5 and 8 the dose will be given as a single dose

DRUG

Glucagon

1 mg injected 3 hr post AZD1656 morning dose on day 5 alt. day 8

Trial Locations (1)

Unknown

Research Site, Chula Vista

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY